Gedeon Richter PLC (RGEDF) Fair Value & Analysis
Healthcare · US · Market cap $7.0B
Gedeon Richter PLC
RGEDF · US
Fair value as of: Aug 13, 2026
From 24 valuation models · updated yesterday
Share price +6.6% over the past month.
A solid business, screening 115% undervalued on our models.
What matters now
- The rarer combination: high quality (74/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The price is below even our cautious bear case ($60.27). The market is more pessimistic than our downside scenario.
- A fairly wide model range ($60.27 to $111.43) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range $10.78 – $42.77 · fair‑value band $60.27 – $111.43 · the $41.50 price screens below the $89.14 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Gedeon Richter PLC (RGEDF) currently trades at $41.50, while our model-based Fair Value estimate is $89.14, implying the stock looks roughly 114.8% undervalued today. The Quality Score stands at 74/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Gedeon Richter PLC generated revenue of $811B at a net margin of 24.8%. Revenue declined 1.7% year over year. It earns a return on equity of 16.4%. The balance sheet holds a net cash position of $175B. Fundamentals as of Aug 13, 2026
Our scenario range runs from $60.27 (bear case) to $111.43 (bull case); at $41.50, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 3% below its 52-week high and 52% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 115%, RGEDF screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models ($82.55) versus Asset-Based ($16.34). Highest evidence: Growth DCF (80).
Notify me when RGEDF reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 74 · Market factors (momentum, volatility) 77
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. It offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids; and Femtech, a digital therapeutic solution to enhance women's lives.
Full company description
Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. It offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids; and Femtech, a digital therapeutic solution to enhance women's lives. It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as products for the prevention and treatment of various cardiovascular diseases. In addition, it produces various over-the-counter products for various health problems comprising Panangin for heart support; Escapelle and Postinor, which are emergency contraceptive pills; Stopdiar and Nifuroxazide to treat diarrhea; RICHTER CycleBalance for infertility and PCOS; Curiosin for wound healing; Groprinosin for antiviral and immunostimulant; Folik, a pregnancy supplement; Moilec for back and joint pain; Fasconal, a pain relief tablet; Lordestin for allergies; Magnezin, a magnesium supplement; Aflamil, an anti-inflammatory and antirheumatic cream; and Oralsept, a sore throat and local anesthetic. Further, it engages in the provision of financial accounting, social and welfare, portfolio management, catering, carriage transportation, engineering, asset management, and biotechnological manufacturing and research services; pharmaceutical retail; trading of biotech products; and sale of medical equipment. It has strategic co-development and license agreement with Adalvo Ltd. for a proposed bioequivalent to Semaglutide injection, a GLP-1 receptor agonist indicated for chronic weight management. Additionally, it has a strategic research collaboration with FimmCyte AG for the development of first-in-class antibody, "FMC2', for the treatment of endometriosis. The company was founded in 1901 and is headquartered in Budapest, Hungary.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Gedeon Richter PLC reported revenue of $923B in FY2025 versus $631B in FY2021, a compound +10.0%/yr. Reported net income was $231B in FY2025, compounding +13.4%/yr from FY2021.
of which total revenue +9.9 pp · buybacks/dilution +0.1 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch RGEDF: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 624 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹8,500 | ₹1,932 | -77% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,915 | ₹1,163 | -76% |
| PharmaEssentia Corporation 6446 | 1,440 TWD | 233.93 TWD | -84% |
| Cipla Limited CIPLA | ₹1,463 | ₹1,001 | -32% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,167 | ₹703.32 | -40% |
| Lupin Limited LUPIN | ₹2,281 | ₹2,477 | +9% |
| Mankind Pharma Limited MANKIND | ₹2,433 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,200 | ₹874.79 | -27% |
Compare Gedeon Richter PLC with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Gedeon Richter PLC (RGEDF) overvalued or undervalued?
What is the fair value of RGEDF?
What is the quality score of RGEDF?
What is the revenue of Gedeon Richter PLC (RGEDF)?
What is the net profit margin of RGEDF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Gedeon Richter PLC and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.